ASX:RACRace Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Race Oncology Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.34 -0.01 (-2.86 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.34Now: A$0.34▼A$0.3750-Day RangeA$0.34MA: A$0.34▼A$0.3452-Week RangeA$0.05Now: A$0.34▼A$0.87Volume76,322 shsAverage VolumeN/AMarket Capitalization$39.30 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Race Oncology Limited operates as a specialty pharmaceutical company in Australia. It develops Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Race Oncology. Previous Next 2.4 Community Rank Outperform VotesRace Oncology has received 19 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRace Oncology has received 20 “underperform” votes. (Add your “underperform” vote.)Community SentimentRace Oncology has received 51.28% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Race Oncology and other stocks. Vote “Outperform” if you believe RAC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RAC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRace Oncology does not currently pay a dividend.Dividend GrowthRace Oncology does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Race Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$39,475.00 in company stock and sold A$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Race Oncology is -9.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Race Oncology is -9.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRace Oncology has a P/B Ratio of 6.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.08 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:RAC Previous Symbol CUSIPN/A CIKN/A Webwww.raceoncology.com Phone61 3 9097 1656Debt Debt-to-Equity RatioN/A Current Ratio7.25 Quick Ratio7.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$159,371.00 Price / Sales246.60 Cash FlowA$0.01 per share Price / Cash Flow24.29 Book ValueA$0.05 per share Price / Book6.80Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares115,592,000Market Cap$39.30 million Next Earnings DateN/A OptionableNot Optionable Receive RAC News and Ratings via Email Sign-up to receive the latest news and ratings for RAC and its competitors with MarketBeat's FREE daily newsletter. Race Oncology (ASX:RAC) Frequently Asked Questions How has Race Oncology's stock been impacted by COVID-19 (Coronavirus)? Race Oncology's stock was trading at A$0.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RAC shares have decreased by 4.2% and is now trading at A$0.34. View which stocks have been most impacted by Coronavirus. How were Race Oncology's earnings last quarter? Race Oncology Ltd (ASX:RAC) released its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter. View Race Oncology's earnings history. Has Race Oncology been receiving favorable news coverage? Media stories about RAC stock have trended very negative this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Race Oncology earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Race Oncology. Who are some of Race Oncology's key competitors? Some companies that are related to Race Oncology include Resverlogix (RVX), Orgenesis (ORGS), Matinas Biopharma (MTNB), Predictive Technology Group (PRED), Monash IVF Group (MVF), Faron Pharmaceuticals Oy (FARN), BioTime (BTX), Lineage Cell Therapeutics (LCTX), Matinas BioPharma (MTNB), Imugene (IMU), Verseon (VSN), MediGene (MDG1), BiomX (PHGE), Immunoprecise Antibodies (IPA) and Lineage Cell Therapeutics (LCTX). View all competitors. What other stocks do shareholders of Race Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Race Oncology investors own include Pilbara Minerals (PLS), Mount Gibson Iron (MGX) and Mesoblast (MESO). Who are Race Oncology's key executives? Race Oncology's management team includes the following people: Mr. Peter Laurence Molloy, MD, CEO & Director (Age 65)Dr. Gordon Beck, Sr. VP of Bus. Devel.Dr. Samar Al-Behaisi, Chief Medical Officer & VP of Medical AffairsMr. Peter G. Webse B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. (Age 56) What is Race Oncology's stock symbol? Race Oncology trades on the ASX under the ticker symbol "RAC." What is Race Oncology's stock price today? One share of RAC stock can currently be purchased for approximately A$0.34. How big of a company is Race Oncology? Race Oncology has a market capitalization of $39.30 million and generates $159,371.00 in revenue each year. What is Race Oncology's official website? The official website for Race Oncology is www.raceoncology.com. How can I contact Race Oncology? The company can be reached via phone at 61 3 9097 1656. This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
